Jaguar Health Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing

Key Facts

1Jaguar Health announced a 1-for-15 reverse stock split effective September 17, 2026.

2The move is intended to regain compliance with Nasdaq's minimum bid price requirement for continued listing.

3Subsidiary Napo Pharmaceuticals advanced its clinical trial for Microvillus Inclusion Disease (MVID) into an extension phase.

In a move reflecting the challenges small-cap biotech firms face in maintaining their status on major exchanges, Jaguar Health has announced a 1-for-15 reverse stock split. Scheduled to take effect on September 17, 2026, the action is designed to increase the per-share price to regain compliance with Nasdaq's minimum bid price requirements for continued listing. This corporate restructuring occurs as the company continues to advance its clinical pipeline, with its subsidiary Napo Pharmaceuticals moving its Microvillus Inclusion Disease (MVID) trials into an extension phase.

According to reports, the stock faced selling pressure following the announcement, dropping over 6% as investors weighed the implications of the consolidation. Per market data, JAGX closed at $0.3189 on September 14, 2026, having traded within a range of $0.29801 to $0.3355 during that session. Such volatility is characteristic of companies undergoing capital restructuring to meet exchange standards, as the market adjusts to a significantly reduced share count and a higher nominal price per unit.

Traders should watch for the commencement of split-adjusted trading on September 17, 2026, which will be the primary catalyst for the stock's immediate price discovery. While the upcoming economic calendar shows no major sector-specific events in the next few days, the long-term outlook remains tied to the clinical progress of Napo Pharmaceuticals. Monitoring the safety and efficacy data from the ongoing MVID trial extension will be crucial for assessing the company's fundamental value post-split.